1.Nsi-189 can Enhance cognition and memory formation 
2.Nsi-189 can Anxiolytic properties 
3.Nsi-189 can Anti-depressive effect
4.Nsi-189 can Treatment of Alzheimer's and Parkinson's disease 
5.Nsi-189 can Increase coordination 6.Nsi-189 can Improves mood
7.Nsi-189 can Help fight fatigue 
8.Nsi-189 can Prevent oxidation within the brain 
9.Nsi-189 can Treat alcohol related brain damage

SI-189 successfully completed a phase I clinical trial for MDD in 2011, where it was administered to 41 healthy volunteers. A phase Ib clinical trial for treating MDD in 24 patients started in 2012 and completed in July 2014, with results published in December 2015. Neuralstem is now preparing to initiate phase II clinical studies for MDD in the first quarter of 2016, with results expected in the second half of 2017. In the two clinical studies conducted thus far, NSI-189 has shown statistically significant effectiveness in reducing depressive symptoms, has been found to be safe and well-tolerated (with no major adverse effects observed), and has been found to improve cognitive deficits in depressed patients. In addition to MDD, Neuralstem intends to pursue clinical development of NSI-189 for a variety of other neurological conditions, including traumatic brain injury, Alzheimer's disease, post-traumatic stress disorder, stroke, and natural cognitive and memory decline in aging.